Literature DB >> 2496560

Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.

A Caenazzo1, F Pietrogrande, G Polato, E Piva, M Masiero, D Sgarabotto, A Girolami.   

Abstract

Platelet-derived growth factor (PDGF) is thought to take part in the genesis of bone marrow fibrosis that can be found in patients with myeloproliferative diseases. We evaluated platelet mitogenic activity as the difference between serum and plasma activity in 8 patients with myeloproliferative disease. We observed a trend of lower values in 2 cases of polycythemia vera and 2 cases of essential thrombocythemia, as seen by other authors. Two patients suffering from chronic myeloid leukemia were within the normal range. In contrast, our 2 cases of idiopathic myelofibrosis showed increased levels. If confirmed by further studies, this could suggest a pathogenetic relationship between increased levels of PDGF and bone marrow fibrosis, and give differential diagnostic significance to the PDGF mitogenic assay in myeloproliferative diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496560     DOI: 10.1159/000205544

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

Review 1.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

Review 2.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis.

Authors:  Frederike Kramer; Jens Dernedde; Artur Mezheyeuski; Rudolf Tauber; Patrick Micke; Kai Kappert
Journal:  Haematologica       Date:  2019-10-31       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.